Clinical trials: Staphylococcus Aureus Skin Infection
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS2 (NCT00107978)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 1,035 people
- Sponsor
- Cumberland Pharmaceuticals
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Trial name
- NCT02814916
- Testing
- Dalbavancin, Vancomycin, Oxacillin
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 199 people
- Sponsor
- AbbVie
Skin Diseases, Infectious, Skin Diseases, Bacterial
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.
- Conditions
- Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections
- Trial name
- NCT00228982
- Testing
- Ceftobiprole medocaril, Vancomycin
- Volunteers
- 784 people
- Sponsor
- Basilea Pharmaceutica
Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
This is a Phase I/IIa trial designed to evaluate topical bacteriophage therapy in patients with diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection, Staphylococcus Aureus Infection, Acinetobacter Infection
- Trial name
- REVERSE (NCT04803708)
- Testing
- TP-102
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Technophage, SA
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with acute bacterial skin and soft tissue infections.
- Trial name
- NCT01984684
- Testing
- delafloxacin, vancomycin, aztreonam
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Melinta Therapeutics, Inc.
Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA), (Susceptible or Methicillin Resistant)
Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus
The study investigates the safety and efficacy of PMX-30063 in patients treated for acute bacterial skin and skin-structure infection (ABSSSI).
- Trial name
- NCT01211470
- Testing
- Daptomycin, PMX-30063-investigational drug
- Where
- 8 sites in Canada, Russia and 1 more
- Volunteers
- 215 people
- Sponsor
- PolyMedix, Inc.
Bacterial Infections, Staphylococcal Vaccines
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag).
- Conditions
- Bacterial Infections, Staphylococcal Vaccines, Immunotherapy, Active, Staphylococcal Skin Infections
- Trial name
- NCT01018641
- Testing
- SA3Ag vaccine, Blood draw, Colonization swab samples
- Where
- 5 sites in Australia
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- Pfizer
Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
This was a randomized, double-blind, placebo-controlled, ascending single dose safety, tolerability, and pharmacokinetic study of orally administered EDP-322. This study was conducted at a single site.
- Trial name
- NCT00989872
- Testing
- EDP-322
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Skin Diseases, Infection
Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects
The main purpose of this study is to compare the safety and efficacy of tigecycline versus clindamycin (including subjects treated with vancomycin) in pediatric subjects (aged 8 to 17 years) with complicated skin and skin…
- Trial name
- NCT00911573
- Testing
- Tigecycline, Clindamycin (or Vancomycin if needed)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infection, Soft Tissue, Infection, Wound
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
This study focuses on a new drug delivery system (Direct Antibiotic Delivery) to treat soft tissue infections. In this study, cefazolin is delivered directly to the target tissues using subcutaneous injection of antibiotic…
- Conditions
- Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
- Trial name
- DAD (NCT01238276)
- Testing
- Cefazolin, Silberg Tissue Preparation System
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sonescence, Inc.
Infections, Soft Tissue
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
The study evaluates the safety, immunogenicity, and efficacy of the GSK S. aureus candidate vaccine (GSK3878858A) when administered to two groups: healthy adults (dose-escalation phase) and adults aged 18 to 64 years with a…
- Trial name
- NCT04420221
- Testing
- Sa-5Ag half dose non-adjuvanted, Sa-5Ag full dose non-adjuvanted, Sa-5Ag half dose adjuvanted
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Infection, Bacterial Infection
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections.
- Trial name
- NCT02052388
- Testing
- Daptomycin, Brilacidin
- Where
- 4 sites in United States
- Volunteers
- 215 people
- Sponsor
- Cellceutix Corporation